李太生教授团队:高剂量静脉注射免疫球蛋白——COVID-19重症患者安全有效的普适疗法

2020-05-04 李太生 北京协和医院

作者:中国医学科学院 北京协和医学院 北京协和医院 林铃 曹玮 李太生

作者:中国医学科学院 北京协和医学院 北京协和医院 林铃 曹玮 李太生*

2019年12月,严重急性呼吸道综合征冠状病毒2型(SARS-CoV-2)爆发,传播迅速。截至目前为止,虽有许多经验性治疗方案,包括现有的和新的抗病毒药物、类固醇和中药等,但对于严重SARS-CoV-2肺炎的最佳治疗策略仍不清楚。

2020年3月下旬,Open Forum Infectious Diseases发布了李太生及阮连国团队对于2019冠状病毒疾病(COVID-2019)重症患者的一篇简短报告《高剂量静脉注射免疫球蛋白可作为新冠病毒病(COVID-19)病情恶化患者的一种治疗选择》(High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019)。

在此篇案例报告中,李太生等人报告了3例接受大剂量静脉注射免疫球蛋白(IVIg)为主要治疗的重症SARS-CoV-2感染的肺炎患者,经过治疗,3例患者无论从临床还是影像学表现上都有很好的改善。提示基于IVIg潜在的免疫调节机制和被动免疫的功能,临床重症、危重症患者早期给予高剂量IVIg可能是有益的。

640_wps图片.jpg

病例介绍

病例1

56岁男性,发热、咽痛2日,最高体温(Tmax) 38.2 ℃,普通抗病毒及抗菌药物治疗无效。2020年1月22日入院CT提示右侧弥散性间质斑片影及胸膜增厚,鼻咽拭子检测SARS-CoV-2阳性。

患者于入院第5天出现呼吸道症状加重,血氧饱和度91%,炎症指标升高明显,CT示肺部病变加重。由普通型快速进展为重型。

入院第7天予IVIg 25 g,连续5天输注。使用当日,患者体温正常,5天后情况好转,血氧饱和度恢复至98%,炎症指标降低,影像学好转,核酸检测两次阴性,于2月5日出院。

图片1.png

图1 患者1自2020年1月19日至2月5日的症状,CT平扫和治疗

病例2

34岁男性,发热、干咳10日,Tmax 38.5 ℃,合并高血压病病史。因呼吸急促就诊,查鼻咽拭子SARS-CoV-2阳性。2020年1月29日入院后血氧饱和度90%,实验室检查示血小板减少,肌酸激酶(CK)、肌红蛋白(Myo)升高,CT示双侧多发浸润及浑浊,评估为重型。立即予IVIg,25 g连续5日输注。使用第2日,患者呼吸困难症状逐渐改善,2月3日复查CT炎症明显吸收,核酸检测两次阴性,于2月5日出院。

图片2.png

图2.患者2 IVIG治疗前后CT平扫

病例3

35岁女性,低热,咳嗽,1月20日 Tmax 37.3 ℃。鼻咽拭子SARS-CoV-2阳性,诊断为COVID-2019。

1月29日,患者病情加重,出现呼吸短促,血氧饱和度降低,淋巴细胞进一步减少,炎症指标持续升高,CT见病变范围增大。由普通型快速进展为重型。予IVIg,25 g连续5日输注,同时予甲泼尼龙40 mg/d×3 d。使用第一天,患者体温正常,两天后血氧饱和度恢复,症状改善。复查胸CT好转,核酸检测两次阴性,于2月9日出院。

 

图片3.png

图3  患者3自2020年1月19日至2月9日的症状,CT平扫和治疗

病例总结与分析

根据患者以轻微或中度的非特异性症状发病,结合患者CT影像学显示病变从肺外带开始,提示病毒感染之后可出现病毒血症阶段,当病毒引起针对器官和组织的继发性损伤发生时,包括肺部、心脏、胃肠道等均会出现损伤,甚至可以引起全身的炎症因子风暴。实验室检查主要提示为炎症指标升高,淋巴细胞进行性减少。

基于以上观察,williamhill asia 提出了在疾病发展即将或刚开始进入加速阶段的时候,有效抑制炎症的级联反应,可以使患者免于致命的免疫介导的损伤。

因此,发病早期给予重症患者每天每公斤体重0.3~0.5 g的高剂量IVIg作为一种有效和安全的免疫调节剂,或可为一种治疗选择。

(本文经李太生教授授权发布,转载请申请)

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-09-26 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-11-18 xzw113
  4. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-11-25 amy0550
  5. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2045162, encodeId=701b204516262, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Jul 16 18:39:22 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698091, encodeId=42ed1698091b3, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Sep 26 00:39:22 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035221, encodeId=188820352210e, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Wed Nov 18 07:39:22 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942122, encodeId=a61d1942122b2, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Wed Nov 25 13:39:22 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283910, encodeId=8ec1128391011, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284104, encodeId=c992128410429, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492505, encodeId=ae331492505a9, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513423, encodeId=279f1513423ae, content=<a href='/topic/show?id=2cff61392cb' target=_blank style='color:#2F92EE;'>#李太生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61392, encryptionId=2cff61392cb, topicName=李太生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=316410549461, createdName=ms306040998833292, createdTime=Wed May 06 04:39:22 CST 2020, time=2020-05-06, status=1, ipAttribution=)]

相关威廉亚洲官网

Rhinology:鼻腔分泌物中的特异性免疫球蛋白E可用于局部过敏性鼻炎的诊断

最近,有研究人员在局部过敏性鼻炎(LAR)中详细调查了血清特异性免疫球蛋白E(slgE)和鼻过敏原激活测试(NAPT)的诊断价值。研究是一个前瞻性的单中心研究,总共包括了212名慢性鼻炎患者。其中73名患者为血清lgE阴性和局部嗜酸性粒细胞阳性。10名健康参与者为对照。所有的参与者完成了相关的调查问卷,并利用视觉模拟评分、血清slgE测试和NAPT对相关情况进行了评估。研究发现,14名患者具有阳性

Neurology:长期IVIg期间应该警惕血栓事件

一项专门针对给予了 IVIg 的炎性神经病患者的研究发现,11.3%的患者在2年内发生了 TEE。发生血栓事件的患者比没有发生血栓事件的人更有可能合并冠心病病史、活动能力差以及心血管危险因素。

J Allergy Clin Immunol:鼻息肉慢性鼻窦炎患者中免疫球蛋白G能够调控促炎性lgE响应

鼻息肉慢性鼻窦炎(CRSwNP)通常可以通过多克隆lgE个体基因型的局部产生来鉴定。虽然组织lgE浓度能够达到几千kU/L,鼻息肉中lgE调节的炎症是通过怎样的机制来调控的仍旧不清楚。最近,有研究人员探索了是否鼻息肉中局部诱导的lgG抗体能够抑制lgE调节的促炎性响应。研究人员从草花粉过敏的CRSwNP和非过敏性对照受试者中采集了鼻息肉匀浆。研究发现,鼻息肉中,lgG在控制lgE调节的炎症响应方面

Lancet:静脉注射免疫球蛋白联合环孢素治疗高耐药风险川崎病

研究认为,静脉注射免疫球蛋白联合环孢素可有效治疗免疫球蛋白耐药高风险的川崎病患者

Arthritis Rheumatol:预测利妥昔单抗治疗风湿和肌肉骨骼疾病期间严重感染和低丙种球蛋白血症的影响

应在基线和每个RTX周期之前监测免疫球蛋白,以识别有SIEs风险的患者。

FDA批准Xembify治疗原发性免疫缺陷

Grifols是一家全球领先的血浆衍生药物生产商,近日宣布,其新的20%皮下免疫球蛋白Xembify®已获得美国食品和药品监督管理局(FDA)的批准用于治疗原发性免疫缺陷。

拓展阅读

李太生:医生要高度敏感,将“艾滋溺水者”尽早捞上来

我国艾滋病防治近年来取得显著效果,但临床上仍有一小部分感染者进入艾滋病晚期、病情危重时才被诊断,因而丧失了治疗机会更快走向死亡。这些人为什么被延迟诊断进而危及生命?北京协和医院感染内科李太生教授团队分析了协和医院乃至北京市4家艾滋病治疗定点医院收治的住院患者资料后发现,缩短诊断时间,有赖于加强综合医院及基层医院对艾滋病临床表现及机会性感染疾病的辨识力、敏感度。

李太生:让艾滋病患者有“质量”的活下去

青砖绿瓦、雕梁画栋的北京协和医院老楼,以特有的庄重和静美,矗立于繁华的王府井大街。

老楼二层,一间不足10平方米、陈设普通的办公室里,感染内科主任李太生正与助手讨论一位来自农村丙肝合并感染艾滋病患者的治疗方案。

语速快、肢体语言丰富、有一股自

京港感染医师论坛 2013:中枢神经系统感染诊治体会

11月16日,在第二届京港感染医师论坛主题报告会上,北京协和医院内科教授、博士生导师,感染内科主任,中华医学会传染病与寄生虫分会副主任委员兼艾滋病学组组长,中华医学会热带病和寄生虫分会主任委员李太生教授作了题为“中枢神经系统感染诊治体会”的报告。 李太生教授首先逐一分析了三个临床症状都为发热伴意识障碍的病例并指出只有第二个病例为脑膜炎奈瑟菌引起的中枢神经系统感染。 随后,李教授逐一讲解了细

我国艾滋病诊疗30年变迁与回顾——在临床研究中前行

  从1985年北京协和医院报告我国首例艾滋病患者直至2002年,我国艾滋病诊治状况基本上是,药物价格昂贵,仅少数患者可以获得治疗。而从2003年至今10年间,随着“四免一关怀”政策的颁布,我国艾滋病临床诊治水平明显提高。去年12月1日艾滋病日,我国学者已提出,艾滋病已变成与高血压、糖尿病、冠心病类似的慢性病,虽不可治愈,但经过治疗能长期存活。本文对30年来我国艾滋病诊疗变迁进行回顾。